The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
GlobalData on MSN15d
EC approves AstraZeneca’s Fasenra for EGPA treatmentFasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback